XML 133 R42.htm IDEA: XBRL DOCUMENT
v3.25.1

Related Party Agreements (Narrative) (Details) |  |  |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Jan. 01, 2025 shares | Jan. 01, 2024 shares | Jan. 01, 2017 USD ($) shares | Jul. 26, 2016 USD ($) shares | Mar. 13, 2015 | Jul. 31, 2016 | Dec. 31, 2024 USD ($) item shares | Dec. 31, 2023 USD ($) shares
Related Party Agreements |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  | $ 6,512,000 | $ 4,398,000
Preferred stock voting rights multiplier |  |  |  | 1.1 |  |  |  |
Research and development for licenses acquired |  |  |  |  |  |  | 861,000 | 527,000
General and administrative |  |  |  |  |  |  | 4,135,000 | $ 9,686,000
Unvested restricted stock awards |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  |  |  | 720
At the Market Offering |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  | $ 2,600,000 | $ 163,000
Class A Preferred Shares |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Shares issuable on conversion, per share converted | shares |  |  |  | 1 |  |  |  |
Fortress Biotech, Inc |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Proceeds from related party debt |  |  |  | $ 2,000,000 |  |  |  |
Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses |  |  |  |  |  |  | 50.00% |
Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses |  |  |  |  |  |  | 50.00% |
Shares issued for services (in shares) | shares |  | 7,061 |  |  |  |  | 23,450 | 1,319
Percentage of fully diluted equity |  |  |  |  |  |  | 2.50% | 2.50%
Proceeds from issuance of common shares |  |  |  |  |  |  |  | $ 200,000
Expenses from related party transaction |  |  |  |  |  |  | $ 500,000 | 500,000
Founders agreement term |  |  |  | 15 years |  |  |  |
Agreement renewal term |  |  |  | 1 year |  |  |  |
Paid in kind dividend, period prior to payment date for measuring ownership |  |  |  | 1 day |  |  |  |
Equity fee, period for payment after financing |  |  |  |  |  |  | 5 days |
Equity fee payable in shares (as a percent) |  |  |  |  |  |  | 2.50% |
Cash fee (as a percent) |  |  |  |  |  |  | 4.50% |
Cash fee, period for payment |  |  |  |  |  |  | 90 days |
Change in control fee, multiplier | item |  |  |  |  |  |  | 5 |
Change in control fee, measurement period |  |  |  |  |  |  | 12 months |
Change in control fee, specified rate component |  |  |  |  |  |  | 4.50% |
MSA agreement term |  |  |  |  | 5 years |  |  |
MSA agreement renewal term |  |  |  |  | 5 years |  |  |
Annual consulting fee |  |  |  |  |  |  | $ 500,000 |
Consulting fee when net assets exceed threshold |  |  |  |  |  |  | 1,000,000 |
Net assets threshold |  |  |  |  |  |  | $ 100,000,000 |
Stock dividend (as a percent) |  |  |  | 2.50% |  |  |  |
Fortress Biotech, Inc | At the Market Offering |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Shares issued for services (in shares) | shares |  |  |  |  |  |  | 3,509 |
Proceeds from issuance of common shares |  |  |  |  |  |  | $ 2,600,000 | 4,400,000
Fortress Biotech, Inc | May 2024 Equity Offering |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  | 4,000,000 |
Fortress Biotech, Inc | June 2024 Registered Direct Offering |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  | 2,500,000 |
Fortress Biotech, Inc | October registered direct offering |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  | 4,000,000 |
Fortress Biotech, Inc | Class B Common Shares |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Number of shares converted | shares |  |  |  | 7,250,000 |  |  |  |
Fortress Biotech, Inc | Common shares |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Number of shares issued in conversion | shares |  |  |  | 9,333 |  |  |  |
Fortress Biotech, Inc | Class A Preferred Shares |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Percentage of fully diluted equity |  |  |  |  |  | 2.50% |  |
Number of shares issued in conversion | shares |  |  |  | 250,000 |  |  |  |
Subsequent events | Fortress Biotech, Inc |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Shares issued for services (in shares) | shares | 69,046 |  |  |  |  |  |  |
Parent Company | Founders Agreement | Fortress Biotech, Inc |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Percentage of fully diluted equity |  | 2.50% |  |  |  |  |  |
Research and development for licenses acquired |  |  |  |  |  |  | 600,000 | 500,000
General and administrative |  |  |  |  |  |  | 300,000 | 100,000
Parent Company | Subsequent events | Founders Agreement | Fortress Biotech, Inc |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Percentage of fully diluted equity | 2.50% |  |  |  |  |  |  |
Director |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  | 100,000
Annual consulting fee |  |  |  |  |  |  | $ 50,000 |
Value of shares granted as compensation |  |  |  |  |  |  |  | $ 50,000
Director | Unvested restricted stock awards |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  |  | 0 | 144
Director | Maximum |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Value of shares granted as compensation |  |  |  |  |  |  | $ 50,000 |
Number of shares granted as compensation | shares |  |  |  |  |  |  | 200 |
Director | Dr. Rosenwald |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  | $ 50,000 |
Director | Mr. Jin |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  | 12,500 |
Chairman of Board of Directors |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  | $ 60,000 | $ 110,000
Annual consulting fee |  |  | $ 60,000 |  |  |  |  |
Value of shares granted as compensation |  |  |  |  |  |  |  | $ 50,000
Chairman of Board of Directors | Unvested restricted stock awards |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  |  | 0 | 144
Chairman of Board of Directors | Maximum |  |  |  |  |  |  |  |
Related Party Agreements |  |  |  |  |  |  |  |
Value of shares granted as compensation |  |  | $ 50,000 |  |  |  |  |
Number of shares granted as compensation | shares |  |  | 200 |  |  |  |  |

X
- Definition The period of time for which the agreement may be renewed. + References No definition available. + Details
Name: | mbio_AgreementRenewalTerm
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The term of the agreement. + References No definition available. + Details
Name: | mbio_AgreementTerm
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the amount of annual consulting fees. + References No definition available. + Details
Name: | mbio_AnnualConsultingFees
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash fee payable as a percentage of annual net sales. + References No definition available. + Details
Name: | mbio_CashFeeAsPercentageOfAnnualNetSales
Namespace Prefix: | mbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of days after the end of the calendar year allowed for payment of the cash fee. + References No definition available. + Details
Name: | mbio_CashFeePaymentPeriod
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of time for measurement of net sales used as a component in the calculation of the change in control fee. + References No definition available. + Details
Name: | mbio_ChangeInControlFeeMeasurementPeriodForNetSales
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The multiple applied to the product of sales and the specified rate, to determine the change in control fee. + References No definition available. + Details
Name: | mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate
Namespace Prefix: | mbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The specified rate component in the calculation of the change in control fee. + References No definition available. + Details
Name: | mbio_ChangeInControlFeeSpecifiedRateComponent
Namespace Prefix: | mbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity. + References No definition available. + Details
Name: | mbio_DilutedOutstandingEquityPercentage
Namespace Prefix: | mbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares granted, or to be granted, as a component of director compensation. + References No definition available. + Details
Name: | mbio_DirectorCompensationNumberOfSharesGranted
Namespace Prefix: | mbio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The market value of shares granted, or to be granted, as a component of director compensation. + References No definition available. + Details
Name: | mbio_DirectorCompensationValueOfSharesGranted
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of days after closing of equity or debt financing allowed for payment of the equity fee. + References No definition available. + Details
Name: | mbio_EquityFeePaymentPeriod
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of equity or debt financing payable as an equity fee. + References No definition available. + Details
Name: | mbio_EquityFeePercentageOfFinancing
Namespace Prefix: | mbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the amount of net assets in excess of liabilities. + References No definition available. + Details
Name: | mbio_ExcessInNetAssetsValue
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This element represents the agreement term with the founders. + References No definition available. + Details
Name: | mbio_FoundersAgreementTerm
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the increase in the amount of annual consulting fees. + References No definition available. + Details
Name: | mbio_IncreaseInAnnualConsultingFees
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The term of the agreement renewal term + References No definition available. + Details
Name: | mbio_MsaAgreementRenewalTerm
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of days prior to the dividend payment date that the outstanding capitalization is to be measured. + References No definition available. + Details
Name: | mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses + References No definition available. + Details
Name: | mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses
Namespace Prefix: | mbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses + References No definition available. + Details
Name: | mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses
Namespace Prefix: | mbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The multiplier applied to shares of stock to determine the voting rights per share. + References No definition available. + Details
Name: | mbio_PreferredStockVotingRightsMultiplier
Namespace Prefix: | mbio_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_ConversionOfStockSharesConverted1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_ConversionOfStockSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued for each share of convertible preferred stock that is converted. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16 + Details
Name: | us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + References No definition available. + Details
Name: | us-gaap_OperatingCostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage rate used to calculate dividend payments on preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_PreferredStockDividendRatePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromRelatedPartyDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_FortressBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_May2024EquityOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_June2024RegisteredDirectOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_OctoberRegisteredDirectOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityOwnedSubsidiaryUnconsolidatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mbio_SecondAmendedAndRestatedFoundersAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_DrLindsayA.RosenwaldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mbio_Mr.DavidJinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |